Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30⁺ lymphoma.

"Declarations Ethics approval and consent to participateThis study was conducted in compliance with the principles of the Declaration of Helsinki. Ethics approval from the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, was obtained before the start of the study. Written informed consent was obtained from all participants. This trial was registered in the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662). Consent for publicationWritten informed consent for publication was obtained. Competing interestsAuthors H.Z., S.Z., and T.Z. were employed by Wuhan Bio-Raid Biotechnology Co., Ltd.. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. Competing interests Authors H.Z., S.Z., and T.Z. were employed by Wuhan Bio-Raid Biotechnology Co., Ltd.. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest."

"Funding This work was supported by funding from the Key Program of the National Natural Science Foundation of China (81830008 to Dr. J.Z.), the National Natural Science Foundation of China (82070211 and 81670152 to Dr. L.H.), the National High Technology Research and Development Program of China (863 program 2014AA020532, to Dr. L.H.), the Milstein Medical Asian American Partnership Foundation (2018 MMAAP Foundation Hematology Fellowship Award, to Dr. L.H.) and the Young Top-notch Talent Cultivation Program of Hubei Province (to Dr. L. H.)."

"Trial registration The trial was registered with the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662)."